Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Official Title
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Acronym
Not provided
Organization
Revolution Medicines, Inc.INDUSTRY
Status Module
Record Verification Date
Feb 2023
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jul 2, 2019Actual
Primary Completion Date
Feb 8, 2022Actual
Completion Date
Feb 8, 2022Actual
First Submitted Date
Jun 14, 2019
First Submission Date that Met QC Criteria
Jun 14, 2019
First Posted Date
Jun 18, 2019Actual
Results Waived
Not provided
Results First Submitted Date
Feb 8, 2023
Results First Submitted that Met QC Criteria
May 31, 2023
Results First Posted Date
Jun 26, 2023Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
May 31, 2023
Last Update Posted Date
Jun 26, 2023Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Revolution Medicines, Inc.INDUSTRY
Collaborators
Name
Class
Sanofi
INDUSTRY
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D); and to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and osimertinib in adult participants with EGFR mutation-positive locally advanced or metastatic NSCLC.
Detailed Description
This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630 in combination with cobimetinib in participants with relapsed/refractory solid tumors; and of RMC-4630 in combination with osimertinib in adult participants with EGFR mutation-positive locally advanced or metastatic NSCLC.
Conditions Module
Conditions
Solid Tumor
Keywords
SHP2
PTPN11
NSCLC
KRAS G12
BRAF Class 3
NF1 LOF
KRAS amplification
KRAS mutations
advanced solid tumor
advanced solid malignancies
bladder cancer
carcinoma, non-small-cell lung
neoplasm, squamous cell
carcinoma, squamous cell
esophageal neoplasms carcinoma, bronchogenic
bronchial neoplasms
lung neoplasms
respiratory tract neoplasms
thoracic neoplasms
neoplasms by site
neoplasms
lung diseases
respiratory tract diseases
gastrointestinal cancer
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
113Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
RMC-4630 and Cobimetinib
Experimental
RMC-4630 and Cobimetinib for oral administration
Drug: RMC-4630
Drug: Cobimetinib
RMC-4630 and Osimertinib
Experimental
RMC-4630 and Osimertinib for oral administration
Drug: RMC-4630
Drug: Drug: Osimertinib
Interventions
Name
Type
Description
Arm Group Labels
Other Names
RMC-4630
Drug
RMC-4630 for oral administration
RMC-4630 and Cobimetinib
RMC-4630 and Osimertinib
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Number of Participants With Adverse Events (AEs).
An adverse event (AE) was defined as any untoward medical occurrence in a participant, temporally associated with the use of a pharmaceutical / an investigational product, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product(s) was also an AE. All AEs and SAEs will be collected from the start of intervention until the safety visit or EOT visit, whichever is later. The number of safety-evaluable participants who experienced at least one treatment-emergent AE was reported per protocol.
AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Number of Participants With Dose Limiting Toxicities (DLTs)
Any toxicities occurring during the DLT observation period (cycle 1) that were considered R/T study treatment, including GR4 AEs; GR3 febrile neutropenia or hemorrhage; GR3 thrombocytopenia with clinically significant bleeding; GR ≥2 pneumonitis; GR3 hypertension or rash which does not improve or remains uncontrolled for >5 or more days despite maximal supportive care; GR3 non hematologic AEs that remain uncontrolled for >72 hours despite maximal supportive care; Concurrent elevation of AST or ALT >3 × ULN & total bilirubin >2 × ULN or international normalized ratio (INR) >1.5 in the absence of cholestasis and other causes; Grade 3 QTcF prolongation based on a triplicate ECG; Ejection fraction <50% with an absolute decrease of >10% from baseline; Retinal vein occlusion any grade; 50% or less dose intensity of RMC4630 and/or cobimetnib or osimertinib due to study drug related toxicity. Refer to protocol for further details.
Cycle 1: Study Day 1 - Study Day 28 (28 days)
Secondary Outcomes
Measure
Description
Time Frame
Cmax
Peak plasma concentration of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Tmax
Time to achieve peak plasma concentration of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Age ≥18 years
For RMC-4630 + Cobimetinib only - Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anti-cancer treatments including approved drugs for oncogenic drivers in their tumor type.
For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not amenable to curative surgery or radiotherapy
For RMC-4630 + Cobimetinib only - Participants must have one of the following genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations
For RMC-4630 + Osimertinib only - Evidence of radiological documentation of progression with osimertinib monotherapy or an osimertinib containing regimen. Participants should not be considered a current candidate for 1st generation EGFR TKI's by the investigator.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Adequate hematological, hepatic, and renal function
Capable of giving signed informed consent form (ICF). Willing and able to compile with study requirements and restrictions
Life expectancy >12 weeks
Female of childbearing potential and males with partners of childbearing potential must comply with effective contraception criteria .
Exclusion Criteria:
Primary central nervous system (CNS) tumors.
Known or suspected leptomeningeal or brain metastases or spinal cord compression.
For RMC-4630 + osimertinib arm only - Known or suspected Small cell, squamous, or pleomorphic lung transformations
Clinically significant cardiac disease
Active, clinically significant interstitial lung disease or pneumonitis
History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO
Known HIV infection or active/chronic hepatitis B or C infection.
Any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
This is a dose escalation study followed by dose expansion.
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Cobimetinib
Drug
Cobimetinib for oral administration
RMC-4630 and Cobimetinib
GDC-0973, XL518
Drug: Osimertinib
Drug
Osimertinib for oral administration
RMC-4630 and Osimertinib
Tagrisso
AZD9291
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Area Under the Curve (AUC)
Area under the plasma concentration time curve of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Accumulation Ratio
AUC ratio (C1D15 versus C1D1) of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Duration of Response (DOR)
Duration of response of RMC-4630 and cobimetinib or RMC-4630 and osimertinib per RECIST v1.1
Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
t1/2
Elimination half-life of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Overall Response Rate (ORR)
ORR is defined as the proportion of participants who achieve a CR or PR per RECIST v1.1. ORR and the corresponding 95% two-sided confidence interval were derived.
Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
Duarte
California
91010
United States
UC Irvine - Chao Family Comprehensive Cancer Center
Orange
California
92868
United States
UC Davis Comprehensive Cancer Center
Sacramento
California
95817
United States
UC San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco
California
94115
United States
University of Colorado Cancer Center
Aurora
Colorado
80045
United States
Moffitt Cancer Center
Tampa
Florida
33612
United States
Winship Cancer Institute, Emory University
Atlanta
Georgia
30322
United States
Northwestern University
Chicago
Illinois
60611
United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore
Maryland
21287
United States
Dana Farber Cancer Institute
Boston
Massachusetts
02215
United States
Karmanos Cancer Institute
Detroit
Michigan
48201
United States
Memorial Sloan Kettering Cancer Center
New York
New York
10021
United States
Ohio State University
Columbus
Ohio
43210
United States
University of Oklahoma - Stephenson Cancer Center
Oklahoma City
Oklahoma
73104
United States
Providence Cancer Institute, Franz Clinic
Portland
Oregon
97213
United States
Fox Chase Cancer Center
Philadelphia
Pennsylvania
19111
United States
Sarah Cannon Research Institute - Tennessee Oncology, PLLC
Nashville
Tennessee
37203
United States
Dell Seton Medical Center at University of Texas
Austin
Texas
78712
United States
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax
Virginia
22031
United States
University of Wisconsin
Madison
Wisconsin
53792
United States
Severance Hospital Yonsei University Health System
Seoul
Seoul Teugbyeolsi
03722
South Korea
Seoul National University Hospital
Seoul
110744
South Korea
Samsung Medical Center - PPDS
Seoul
135-710
South Korea
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40 mg QD 21 days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140mg on D1 and D2 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Osimertinib 80 mg QD.
BG008
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0008
BG0016
BG00212
BG0037
BG00465
BG0057
BG0064
BG0074
BG008113
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Categorical
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
<=18 years
BG0000
BG0010
BG0020
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0005
BG0014
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Number of Participants With Adverse Events (AEs).
An adverse event (AE) was defined as any untoward medical occurrence in a participant, temporally associated with the use of a pharmaceutical / an investigational product, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product(s) was also an AE. All AEs and SAEs will be collected from the start of intervention until the safety visit or EOT visit, whichever is later. The number of safety-evaluable participants who experienced at least one treatment-emergent AE was reported per protocol.
All safety-evaluable participants who experienced at least one treatment-emergent AE.
Posted
Count of Participants
Participants
AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
Units
Counts
Participants
OG0008
OG0016
OG00212
OG003
Title
Denominators
Categories
Title
Measurements
OG0008
OG0016
OG00212
OG003
Primary
Number of Participants With Dose Limiting Toxicities (DLTs)
Any toxicities occurring during the DLT observation period (cycle 1) that were considered R/T study treatment, including GR4 AEs; GR3 febrile neutropenia or hemorrhage; GR3 thrombocytopenia with clinically significant bleeding; GR ≥2 pneumonitis; GR3 hypertension or rash which does not improve or remains uncontrolled for >5 or more days despite maximal supportive care; GR3 non hematologic AEs that remain uncontrolled for >72 hours despite maximal supportive care; Concurrent elevation of AST or ALT >3 × ULN & total bilirubin >2 × ULN or international normalized ratio (INR) >1.5 in the absence of cholestasis and other causes; Grade 3 QTcF prolongation based on a triplicate ECG; Ejection fraction <50% with an absolute decrease of >10% from baseline; Retinal vein occlusion any grade; 50% or less dose intensity of RMC4630 and/or cobimetnib or osimertinib due to study drug related toxicity. Refer to protocol for further details.
DLT-evaluable population was defined as the following: All treated participants in the dose escalation phase who completed the DLT period and received at least 75% of planned dose of RMC-4630 and cobimetinib or RMC-4630 and Osimertinib (ie, not have missed ≥3 doses of RMC-4630 and cobimetinib on the D1D2 intermittent schedule or ≥6 doses of cobimetinib on the 21 on/7 off schedule, or ≥8 doses for reasons other than toxicity) within the DLT observation period (i.e Cycle 1)
Posted
Count of Participants
Participants
Cycle 1: Study Day 1 - Study Day 28 (28 days)
ID
Title
Description
OG000
Intermittent RMC-4630 (D1D4 or D1D2) + Daily Cobimetinib (QD21/7)
Participants who received intermittent dose of RMC-4630 80 mg or 140 mg on D1 and D4 or on D1 and D2 of a 28-day cycle and daily dose of Cobimetinib 20 mg or 40 mg from D1 through D21 and then 7 days off Cobimetinib from D22 to D28 of a 28-day cycle.
Secondary
Cmax
Peak plasma concentration of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Posted
Geometric Mean
Geometric Coefficient of Variation
ng/mL
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Duration of response of RMC-4630 and cobimetinib or RMC-4630 and osimertinib per RECIST v1.1
There were insufficient number of participants with events to calculate.
Posted
Median
95% Confidence Interval
day(s)
Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
ID
Title
Description
OG000
Intermittent RMC-4630 (D1D4 or D1D2) + Daily Cobimetinib (QD21/7)
Participants who received intermittent dose of RMC-4630 80 mg or 140 mg on D1 and D4 or on D1 and D2 of a 28-day cycle and daily dose of Cobimetinib 20 mg or 40 mg from D1 through D21 and then 7 days off Cobimetinib from D22 to D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and intermittent dose of Cobimetinib 40 mg or 60 mg on D1 and D2 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Secondary
t1/2
Elimination half-life of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Posted
Median
Full Range
h
0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Secondary
Overall Response Rate (ORR)
ORR is defined as the proportion of participants who achieve a CR or PR per RECIST v1.1. ORR and the corresponding 95% two-sided confidence interval were derived.
Posted
Number
95% Confidence Interval
% of participants
Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
OG003
Time Frame
AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Description
Summary of serious treatment emergent adverse events in participants who received > / = one dose of RMC-4630 and/or cobimetinib or in all participants who received > / = one dose of RMC-4630 and/or osimertinib.
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
3
4
1
4
4
4
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
gastrointestinal hemorrhage
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG0030 affected7 at risk
EG0040 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 events0 affected4 at risk
large intestinal obstruction
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
small intestinal obstruction
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
vomiting
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
abdominal pain
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
diarrhoea
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
ileus paralytic
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
intestinal obstruction
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
upper gastrointestinal haemorrhage
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pneumonia
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
sepsis
Infections and infestations
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
COVID-19 pneumonia
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pneumonia legionella
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pneumonitis
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
haemoptysis
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypoxia
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pleural effusion
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pulmonary embolism
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dyspnoea
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dehydration
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hyperkalaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypoglycaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hyponatraemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
non-cardiac chest pain
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pyrexia
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
anaemia
Blood and lymphatic system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
thrombocytopenia
Blood and lymphatic system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
myocardial infarction
Cardiac disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0022 affected12 at risk
EG003
acute myocardial infarction
Cardiac disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
cardiac failure acute
Cardiac disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
cognitive disorder
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
headache
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
lethargy
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
deep vein thrombosis
Vascular disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypotension
Vascular disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
jugular vein thrombosis
Vascular disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
alanine aminotransferase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
aspartate aminotransferase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
platelet count decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pathological fracture
Musculoskeletal and connective tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
malignant pleural effusion
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
confusional state
Psychiatric disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
nausea
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
oesophagitis
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
proctalgia
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
rectal haemorrhage
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
diarrhoea
Gastrointestinal disorders
Systematic Assessment
EG0006 affected8 at risk
EG0016 affected6 at risk
EG00211 affected12 at risk
EG0036 affected7 at risk
EG00453 affected65 at risk
EG0057 affected7 at risk
EG0063 affected4 at risk
EG0074 affected4 at risk
nausea
Gastrointestinal disorders
Systematic Assessment
EG0002 affected8 at risk
EG0012 affected6 at risk
EG0023 affected12 at risk
EG003
constipation
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
vomiting
Gastrointestinal disorders
Systematic Assessment
EG0002 affected8 at risk
EG0012 affected6 at risk
EG0022 affected12 at risk
EG003
abdominal pain
Gastrointestinal disorders
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
abdominal distention
Gastrointestinal disorders
Systematic Assessment
EG0002 affected8 at risk
EG0013 affected6 at risk
EG0021 affected12 at risk
EG003
dry mouth
Gastrointestinal disorders
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
ascites
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0012 affected6 at risk
EG0022 affected12 at risk
EG003
fatigue
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0013 affected6 at risk
EG0023 affected12 at risk
EG003
oedema peripheral
General disorders
Systematic Assessment
EG0002 affected8 at risk
EG0012 affected6 at risk
EG0024 affected12 at risk
EG003
pyrexia
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0023 affected12 at risk
EG003
dyspnoea
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0013 affected6 at risk
EG0025 affected12 at risk
EG003
cough
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0023 affected12 at risk
EG003
pleural effusion
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0023 affected12 at risk
EG003
aspartate aminotransferase increased
Investigations
Systematic Assessment
EG0001 affected8 at risk
EG0012 affected6 at risk
EG0022 affected12 at risk
EG003
platelet count decreased
Investigations
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
blood creatine phosphokinase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0013 affected6 at risk
EG0022 affected12 at risk
EG003
lymphocyte count decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
decreased appetite
Metabolism and nutrition disorders
Systematic Assessment
EG0001 affected8 at risk
EG0012 affected6 at risk
EG0021 affected12 at risk
EG003
hypoalbuminaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0012 affected6 at risk
EG0021 affected12 at risk
EG003
hypomagnesaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0013 affected6 at risk
EG0022 affected12 at risk
EG003
dehydration
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
hyponatraemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0014 affected6 at risk
EG0021 affected12 at risk
EG003
anaemia
Blood and lymphatic system disorders
Systematic Assessment
EG0001 affected8 at risk
EG0013 affected6 at risk
EG0025 affected12 at risk
EG003
thrombocytopenia
Blood and lymphatic system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0012 affected6 at risk
EG0023 affected12 at risk
EG003
vision blurred
Eye disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
rash maculo-papular
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
dry skin
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
dizziness
Nervous system disorders
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
fall
Injury, poisoning and procedural complications
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
gait disturbance
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
decubitus ulcer
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
foot fracture
Injury, poisoning and procedural complications
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
skin laceration
Injury, poisoning and procedural complications
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
reticulocyte count increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
nail infection
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
scrotal haemorrhage
Reproductive system and breast disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
non-cardiac chest pain
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
asthenia
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
chills
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
face oedema
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
peripheral swelling
General disorders
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
generalised oedema
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
localised oedema
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
oedema
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
hypoxia
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
nasal congestion
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dyspnoea exertional
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pneumonitis
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
respiratory failure
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
blood alkaline phosphatase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0012 affected6 at risk
EG0021 affected12 at risk
EG003
weight increased
Investigations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0022 affected12 at risk
EG003
blood creatinine increased
Investigations
Systematic Assessment
EG0002 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
gamma-glutamyltranferase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
alanine aminotransferase increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
blood bilirubin increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
white blood cell count decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hypokalaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
weight decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypophosphataemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dry eye
Eye disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0022 affected12 at risk
EG003
dermatitis acneiform
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0022 affected12 at risk
EG003
rash
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
skin hyperpigmentation
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
headache
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
syncope
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
urinary tract infection
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
pneumonia
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
proteinuria
Renal and urinary disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
haematuria
Renal and urinary disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
nephrolithiasis
Renal and urinary disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
sinus tachycardia
Cardiac disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypotension
Vascular disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0022 affected12 at risk
EG003
hypertension
Vascular disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
leukopenia
Blood and lymphatic system disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
periorbital oedema
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
neutropenia
Blood and lymphatic system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dyspepsia
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
abdominal pain upper
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
flatulence
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
gastrooesophageal reflux disease
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
rectal haemorrhage
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
stomatitis
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
gastrointestinal hemorrhage
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
toothache
Gastrointestinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
abdominal discomfort
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
faeces discoloured
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
haematochezia
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
large intestine perforation
Gastrointestinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hernia
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
pain
General disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
swelling face
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
influenza like illness
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
mucosal inflammation
General disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
rhinorrhoea
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dysphonia
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
wheezing
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
haemoptysis
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pulmonary embolism
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pulmonary hypertension
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
sleep apnoea syndrome
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
snoring
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
ejection fraction decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
neutrophil count decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
blood potassium decreased
Investigations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
blood uric acid decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
blood uric acid increased
Investigations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
international normalised ratio increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
protein total decreased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
troponin T increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
troponin increased
Investigations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypocalcaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hyperuricaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
failure to thrive
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
hypoproteinaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hypouricaemia
Metabolism and nutrition disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
leukocytosis
Blood and lymphatic system disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
retinopathy
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
subretinal fluid
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
visual impairment
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
chorioretinopathy
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
retinal haemorrhage
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
detachment of retinal pigment epithelium
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
lacrimation increased
Eye disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
macular oedema
Eye disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pruritus
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hair colour changes
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
alopecia
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
palmer-plantar erythrodysaesthesia syndrome
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
neuropathy peripheral
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
hypoaesthesia
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0021 affected12 at risk
EG003
taste disorder
Nervous system disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
dyskinesia
Nervous system disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
flushing
Vascular disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
oral candidiasis
Infections and infestations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
rash pustular
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0011 affected6 at risk
EG0020 affected12 at risk
EG003
upper respiratory tract infection
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
bronchitis
Infections and infestations
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
onychomycosis
Infections and infestations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pyelonephritis
Infections and infestations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
sepsis
Infections and infestations
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
acute kidney injury
Renal and urinary disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0021 affected12 at risk
EG003
dysuria
Renal and urinary disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
nephropathy
Renal and urinary disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
right ventricular failure
Cardiac disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
anxiety
Psychiatric disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
depression
Psychiatric disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
gastrointestinal stoma complication
Injury, poisoning and procedural complications
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
anisomastia
Reproductive system and breast disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
erectile dysfunction
Reproductive system and breast disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
pelvic pain
Reproductive system and breast disorders
Systematic Assessment
EG0001 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
vaginal haemorrhage
Reproductive system and breast disorders
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Systematic Assessment
EG0000 affected8 at risk
EG0010 affected6 at risk
EG0020 affected12 at risk
EG003
malignant ascites
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and intermittent dose of Cobimetinib 40 mg or 60 mg on D1 and D2 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Units
Counts
Participants
OG0006
OG0016
OG0029
OG0036
OG0045
OG0056
OG0064
OG0074
Title
Denominators
Categories
Title
Measurements
OG0001
OG0010
OG0023
OG0031
OG0040
OG0052
OG0061
OG0072
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
Units
Counts
Participants
OG0008
OG0016
OG00212
OG0037
OG00465
OG0057
OG0064
OG0074
Title
Denominators
Categories
C1D1
Title
Measurements
OG000214± 45
OG001248± 38
OG002469± 42
OG003430± 61
OG004354± 52
OG005449± 27
OG006242± 57
OG007449± 25
C1D15
Title
Measurements
OG000207± 90
OG001266± 64
OG002465± 37
OG003
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Units
Counts
Participants
OG0008
OG0016
OG00212
OG0037
OG00465
OG0057
OG0064
OG0074
Title
Denominators
Categories
C1D1
Title
Measurements
OG0002.94(1.00 to 4.13)
OG0012.00(1.00 to 2.03)
OG0021.99(0.90 to 7.50)
OG0031.02(0.98 to 2.00)
OG0042.00(0.42 to 8.00)
OG0051.92(0.92 to 3.97)
OG0062.03(0.98 to 7.55)
OG0072.95(1.07 to 4.10)
C1D15
Title
Measurements
OG0002.04(1.00 to 4.07)
OG0012.08(0.97 to 4.99)
OG0023.04(1.87 to 7.77)
OG003
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Units
Counts
Participants
OG0008
OG0016
OG00212
OG0037
OG00465
OG0057
OG0064
OG0074
Title
Denominators
Categories
C1D1
Title
Measurements
OG0002570± 34
OG0012580± 30
OG0025510± 38
OG0034610± 39
OG0044700± 38
OG0054720± 26
OG0063360± 28
OG0075920± 15
C1D15
Title
Measurements
OG0003220± 91
OG0013360± 44
OG0026370± 37
OG003
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0030
OG0041
OG0050
OG0060
OG0070
Title
Denominators
Categories
Title
Measurements
OG004NAinsufficient number of participants with events to calculate
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
Units
Counts
Participants
OG0006
OG0016
OG0028
OG0036
OG00455
OG0056
OG0063
OG0073
Title
Denominators
Categories
Title
Measurements
OG0000(0.0 to 45.9)
OG0010(0.0 to 45.9)
OG0020(0.0 to 36.9)
OG0030(0.0 to 45.9)
OG0041.82(0.0 to 9.7)
OG0050(0.0 to 45.9)
OG0060(0.0 to 7.1)
OG0070(0.0 to 7.1)
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 events0 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG00424 affected65 at risk
EG0053 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG00419 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
1 affected
7 at risk
EG00413 affected65 at risk
EG0053 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
2 affected
7 at risk
EG00414 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0049 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG0049 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
3 affected
7 at risk
EG00423 affected65 at risk
EG0052 affected7 at risk
EG0064 affected4 at risk
EG0071 affected4 at risk
1 affected
7 at risk
EG00422 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
1 affected
7 at risk
EG00413 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG00421 affected65 at risk
EG0051 affected7 at risk
EG0062 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0049 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0071 affected4 at risk
1 affected
7 at risk
EG0047 affected65 at risk
EG0050 affected7 at risk
EG0062 affected4 at risk
EG0070 affected4 at risk
4 affected
7 at risk
EG00411 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG00410 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0071 affected4 at risk
2 affected
7 at risk
EG0046 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0055 affected7 at risk
EG0061 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG00414 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0073 affected4 at risk
2 affected
7 at risk
EG00411 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
1 affected
7 at risk
EG0045 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0047 affected65 at risk
EG0052 affected7 at risk
EG0061 affected4 at risk
EG0072 affected4 at risk
1 affected
7 at risk
EG0045 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
4 affected
7 at risk
EG00423 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0071 affected4 at risk
2 affected
7 at risk
EG0047 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG00410 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0062 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0062 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG00411 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0072 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0047 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG00410 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0046 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0047 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0046 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0045 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0045 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0044 events4 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 events0 affected4 at risk
1 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
2 affected
7 at risk
EG00412 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
3 affected
7 at risk
EG0042 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0045 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0071 affected4 at risk
0 affected
7 at risk
EG0044 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0046 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0044 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0046 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0046 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0047 affected65 at risk
EG0050 affected7 at risk
EG0063 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0047 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0044 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0041 affected65 at risk
EG0052 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG00420 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0061 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0042 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0043 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
1 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0041 affected65 at risk
EG0051 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
0 affected
7 at risk
EG0040 affected65 at risk
EG0050 affected7 at risk
EG0060 affected4 at risk
EG0070 affected4 at risk
504
± 71
OG004395± 56
OG005469± 20
OG006286± 38
OG007408± 3
1.08
(1.00 to 2.12)
OG0042.00(0.57 to 23.7)
OG0051.96(0.97 to 2.07)
OG0061.98(1.88 to 2.00)
OG0074.07(4.05 to 4.08)
5580
± 45
OG0045460± 45
OG0055600± 18
OG0064230± 35
OG0075500± 26
22.2
(16.5 to 91.7)
OG00414.4(5.18 to 18.2)
OG00518.4(11.3 to 24.8)
OG00624.6(15.2 to 25.2)
OG007NA(NA to NA)Insufficient timepoints to calculate this data.